MTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo

Breast Cancer Research and Treatment

Volumn 136, Issue 2, 2012, Pages 379-388

  Zhang, Yue ^a   Xu, Song ^a,b   Lin, Jun ^a   Yao, Guangyu ^a   Han, Zelong ^a   Liang, Bo ^a   Zou, Zhenhong ^a   Chen, Zhenguo ^a   Song, Qiancheng ^a   Dai, Yifan ^c   Gao, Tianming ^a   Liu, Anling ^a   Bai, Xiaochun ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

AMP activated protein kinase; Breast cancer; Mammalian target of rapamycin complex 1; Nordihydroguaiaretic acid; Raptor; Tuberous sclerosis complex 2

Indexed keywords

AMINO ACID; CELL PROTEIN; CYCLIN D1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; NORDIHYDROGUAIARETIC ACID; PROTEIN RAPTOR; RAPAMYCIN; TUBERIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; COMPLEX FORMATION; DISEASE MODEL; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; FEMALE; HUMANS; MICE; MICE, NUDE; MULTIPROTEIN COMPLEXES; NORDIHYDROGUAIARETIC ACID; PROTEIN KINASE INHIBITORS; TOR SERINE-THREONINE KINASES; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84868214226     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2270-7     Document Type: Article

References (39)

1. Lu JM, Nurko J, Weakley SM, Jiang J, Kougias P, Lin PH, Yao Q, Chen C (2010) Molecular mechanisms and clinical applications of nordihydroguaiaretic acid (NDGA) and its derivatives: An update. Med Sci Monit 16(5):RA93-RA100
2. Fujiwara T, Takami N, Misumi Y, Ikehara Y (1998) Nordihydroguaiaretic acid blocks protein transport in the secretory pathway causing redistribution of Golgi proteins into the endoplasmic reticulum. J Biol Chem 273(5):3068-3075
3. Sahu SC, Ruggles DI, O'Donnell MW (2006) Prooxidant activity and toxicity of nordihydroguaiaretic acid in clone-9 rat hepatocyte cultures. Food Chem Toxicol 44(10):1751-1757
4. Avis IM, Jett M, Boyle T, Vos MD, Moody T, Treston AM, Martinez A, Mulshine JL (1996) Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest 97(3):806-813
5. Huang JK, Chen WC, Huang CJ, Hsu SS, Chen JS, Cheng HH, Chang HT, Jiann BP, Jan CR (2004) Nordihydroguaiaretic acidinduced Ca2? handling and cytotoxicity in human prostate cancer cells. Life Sci 75(19):2341-2351
6. Shimakura S, Boland CR (1992) Eicosanoid production by the human gastric cancer cell line AGS and its relation to cell growth. Cancer Res 52(7):1744-1749
7. Meyer GE, Chesler L, Liu D, Gable K, Maddux BA, Goldenberg DD, Youngren JF, Goldfine ID, Weiss WA, Matthay KK, Rosenthal SM (2007) Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells. J Cell Biochem 102(6):1529-1541
8. Rose DP, Connolly JM (1990) Effects of fatty acids and inhibitors of eicosanoid synthesis on the growth of a human breast cancer cell line in culture. Cancer Res 50(22):7139-7144
9. Meyer AN, McAndrew CW, Donoghue DJ (2008) Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells. Cancer Res 68(18):7362-7370
10. Seufferlein T, Seckl MJ, Schwarz E, Beil M, Wichert G, Baust H, Luhrs H, Schmid RM, Adler G (2002) Mechanisms of nordihydroguaiaretic acid-induced growth inhibition and apoptosis in human cancer cells. Br J Cancer 86(7):1188-1196
11. Youngren JF, Gable K, Penaranda C, Maddux BA, Zavodovskaya M, Lobo M, Campbell M, Kerner J, Goldfine ID (2005) Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/ HER2/neu receptors and suppresses growth in breast cancer cells. Breast Cancer Res Treat 94(1):37-46
12. Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12(1):21-35
13. Guertin DA, Sabatini DM (2005) An expanding role for mTOR in cancer. Trends Mol Med 11(8):353-361
14. Laplante M, Sabatini DM (2009) mTOR signaling at a glance. J Cell Sci 122(Pt 20):3589-3594
15. Bai X, Jiang Y (2010) Key factors in mTOR regulation. Cell Mol Life Sci 67(2):239-253
16. Efeyan A, Sabatini DM (2010) mTOR and cancer: Many loops in one pathway. Curr Opin Cell Biol 22(2):169-176
17. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307(5712):1098-1101
18. Janes MR, Fruman DA (2010) Targeting TOR dependence in cancer. Oncotarget 1(1):69-76
19. Weigelt B, Warne PH, Downward J (2011) PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 30(29): 3222-3233
20. Huang S, Houghton PJ (2003) Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 3(4):371-377
21. Awada A, Cardoso F, Fontaine C, Dirix L, De Greve J, Sotiriou C, Steinseifer J, Wouters C, Tanaka C, Zoellner U, Tang P, Piccart M (2008) The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics. Eur J Cancer 44(1):84-91
22. deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M (2004) Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 10(23):8059-8067
23. Li M, Zhao L, Liu J, Liu A, Jia C, Ma D, Jiang Y, Bai X (2010) Multi-mechanisms are involved in reactive oxygen species regulation of mTORC1 signaling. Cell Signal 22(10):1469-1476
24. Ma D, Bai X, Zou H, Lai Y, Jiang Y (2010) Rheb GTPase controls apoptosis by regulating interaction of FKBP38 with Bcl-2 and Bcl-XL. J Biol Chem 285(12):8621-8627
25. Bai X, Ma D, Liu A, Shen X, Wang QJ, Liu Y, Jiang Y (2007) Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 318(5852):977-980
26. Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer 9(3):153-166
27. Ma XM, Blenis J (2009) Molecular mechanisms of mTORmediated translational control. Nat Rev Mol Cell Biol 10(5): 307-318
28. Wouters BG, Koritzinsky M (2008) Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 8(11):851-864
29. Brugarolas J, Kaelin WG Jr (2004) Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell 6(1):7-10
30. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, Wang CY, He X, Mac-Dougald OA, You M, Williams BO, Guan KL (2006) TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126(5): 955-968
31. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110(2):163-175
32. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22(2):159-168
33. Yoshida S, Hong S, Suzuki T, Nada S, Mannan AM, Wang J, Okada M, Guan KL, Inoki K (2011) Redox regulates mammalian target of rapamycin complex 1 (mTORC1) activity by modulating the TSC1/TSC2-Rheb GTPase pathway. J Biol Chem 286(37):32651-32660
34. Sarbassov DD, Sabatini DM (2005) Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex. J Biol Chem 280(47):39505-39509
35. Zavodovskaya M, Campbell MJ, Maddux BA, Shiry L, Allan G, Hodges L, Kushner P, Kerner JA, Youngren JF, Goldfine ID (2008) Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells. J Cell Biochem 103(2):624-635
36. Rowe DL, Ozbay T, Bender LM, Nahta R (2008) Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer. Mol Cancer Ther 7(7):1900-1908
37. Li F, Pham JD, Anderson MO, Youngren JF (2009) Nordihydroguaiaretic acid inhibits transforming growth factor beta type 1 receptor activity and downstream signaling. Eur J Pharmacol 616(1-3):31-37
38. Carew JS, Kelly KR, Nawrocki ST (2011) Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol 6(1):17-27
39. Lee MS, Kim D, Jo K, Hwang JK (2010) Nordihydroguaiaretic acid protects against high-fat diet-induced fatty liver by activating AMP-activated protein kinase in obese mice. Biochem Biophys Res Commun 401(1):92-97